Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

271.69 +9.41 (+3.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
53 54 Next >
Is It Time to Buy the Dow Jones' 3 Worst-Performing February (and Now March) Stocks?
Several blue chips have been routed lately, but most of their sell-offs were way overdone. 
Via The Motley Fool
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amgen Inc. (AMGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Amgen Unusual Options Activity For March 15
Via Benzinga
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Amgen Inc. (NASDAQ: AMGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
Price Over Earnings Overview: Amgen
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
These two companies are showering shareholders with market-topping payouts. 
Via The Motley Fool
Amgen Faces Lawsuit For Hiding Its Stupendous Tax Bill Of $10B
Via Benzinga
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
AMGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Amgen Inc. (AMGN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Amgen's Debt Overview
Via Benzinga
What 14 Analyst Ratings Have To Say About Amgen
Via Benzinga
Death Cross Looms Over Amgen Investors
Via Benzinga
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Amgen Inc. (AMGN)
From Robbins LLP
Via Business Wire
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies, 
Via MarketBeat
Exposures COVID-19
A Look Into Amgen's Debt
Shares of Amgen Inc. (NASDAQ:AMGN) fell by 17.83% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials. 
Via Benzinga
AMGN EQUITY ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Amgen Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
From The Rosen Law Firm, P.A.
Via Business Wire
2 Stocks to Buy Near Their 52-Week Lows That Could Help You Beat The Market
Let's follow one of the most basic investment tips: Buy low. 
Via The Motley Fool
AMGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis. 
Via Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
A Bull Market Is Coming: 3 Stocks Near Their 52-Week Lows to Buy Now
It may only be a matter of time before these stocks start to rally. 
Via The Motley Fool
7 Over-$100 Stocks That Are Worth Every Penny
To get most of the best-known stocks, you have to be prepared to pay at least $100 per share. Here are seven stocks to buy. 
Via InvestorPlace
Could This Humira Biosimilar Be a Winner for Amgen?
This Humira biosimilar just launched in the U.S. several weeks ago. 
Via The Motley Fool
3 Value Stocks You'll Regret Not Buying on the Dip
These three undervalued healthcare stocks are solid picks for patient investors. 
Via The Motley Fool
Is Amazon a Blue Chip Stock?
Is Amazon a blue chip stock or does it fit into a different category? Learn more about Amazon.com Inc. and how to categorize it with MarketBeat. 
Via MarketBeat
Want More Reliable Dividend Income? Buy This Dividend King.
This big pharma company possesses a deep drug portfolio and pipeline. 
Via The Motley Fool
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.